Simultaneous Detection of Sars-Cov-2 Igg/Igm Antibodies, Using Gold Nanoparticles-Based Lateral Flow Immunoassay Publisher Pubmed



Ahmadi A^{1, 2} ; Mirzaeizadeh Z^{1, 2} ; Omidfar K^{1, 2} Show Affiliations
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy Published:2021

Abstract

The novel coronavirus disease (COVID-19), known as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), exhibits a strong human-to-human transmission infectivity and could cause acute respiratory infections. Therefore, simple and rapid serological testing is urgently needed to recognize positive cases. In this study, a point-of-care serological test based on lateral flow immunoassay (LFIA) was developed and its application for the simultaneous detection of IgM/IgG antibodies against SARS-CoV-2 was evaluated. The recombinant SARS-CoV-2 antigens were conjugated to the produced colloidal gold nanoparticles and used as the detection reagent. This test required only 10-15 minutes to achieve simultaneous qualitative detection of IgM/IgG antibodies specific to SARS-CoV-2 in 20 μL of serum or plasma samples. The clinical performance and reliability of the assay were evaluated by performing the test with 60 samples and comparing the results of these tests with those obtained via real-time polymerase chain reaction. The sensitivity and specificity of our assay were defined to be 90% and 96.6%, respectively. The presented LFIA was sufficiently sensitive and accurate to be used for the rapid diagnosis of coronavirus disease 2019 in laboratories or in patient care settings, particularly in emergency conditions, in which many samples require to be evaluated on time. © Copyright 2021, Mary Ann Liebert, Inc., publishers 2021.